Value-based contracts — big talk, big deal, or real deal?
Pharmaceutical companies guaranteeing results and paying for failures?
Payers paying more if a cancer patient has a shorter lifespan on a specific drug?
Pharma guaranteeing the control of cholesterol?
A few years ago, these seemed as unlikely as a biosimilar version of a blockbuster biologic. Now value-based contracting (VBC) seems to be the hottest topic in payer-pharmaceutical company relationships.l?
Biosimilars Are Coming, Biosimilars Are Coming!
Biosimilars are knocking at our doors, and they certainly have a lot to say. Biosimilar products are biological products that are approved based on showing that they are highly similar to FDA-approved biological products, known as reference products, showing no clinically meaningful differences in terms of safety and effectiveness.